发明名称 |
TREATMENT OF CANCER USING A CLL-1 CHIMERIC ANTIGEN RECEPTOR |
摘要 |
The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain. |
申请公布号 |
US2016051651(A1) |
申请公布日期 |
2016.02.25 |
申请号 |
US201514805075 |
申请日期 |
2015.07.21 |
申请人 |
Brogdon Jennifer;Ebersbach Hilmar Erhard;Gill Saar;Glass David;Jascur Julia;Kenderian Saad;Mannick Joan;Milone Michael C.;Murphy Leon;Richardson Celeste;Singh Reshma;Wei Lai;Wu Qilong;Yang Qiumei;Zhang Jiquan |
发明人 |
Brogdon Jennifer;Ebersbach Hilmar Erhard;Gill Saar;Glass David;Jascur Julia;Kenderian Saad;Mannick Joan;Milone Michael C.;Murphy Leon;Richardson Celeste;Singh Reshma;Wei Lai;Wu Qilong;Yang Qiumei;Zhang Jiquan |
分类号 |
A61K39/00;A61K31/7068;C07K14/705;A61K45/06;C07K16/28;C07K14/725 |
主分类号 |
A61K39/00 |
代理机构 |
|
代理人 |
|
主权项 |
1. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an anti-CLL-1 binding domain, a transmembrane domain, and an intracellular signaling domain, and wherein said anti-CLL-1 binding domain comprises:
(i) a heavy chain complementary determining region 1 (HC CDR1), a heavy chain complementary determining region 2 (HC CDR2), and a heavy chain complementary determining region 3 (HC CDR3) of any anti-CLL-1 heavy chain binding domain amino acid sequences listed in Table 2; and (ii) a light chain complementary determining region 1 (LC CDR1), a light chain complementary determining region 2 (LC CDR2), and a light chain complementary determining region 3 (LC CDR3) of any anti-CLL-1 light chain binding domain amino acid sequences listed in Table 2. |
地址 |
Cambridge MA US |